Here, we expanded upon those findings by using genetic and pharmacological NLRP3 inhibition to elucidate NLRP3 as the predominate inflammasome sensor responsible for breast tumor-induced IL-1β production in infiltrating myeloid cells. This evidence concerns the gene IL1B and breast neoplasm.